Vesugen (20 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: one subcutaneous injection once daily, every day of the course, with no off days built into the schedule. Titration is slow and deliberate, holding two weeks at 500 mcg and two weeks at 1.0 mg before moving to the upper steps, and many protocols stabilize in the 1 to 1.5 mg range rather than continuing to 2 mg. Injections go into subcutaneous tissue at 45 to 90 degrees with sites rotated systematically across abdomen, thighs, and upper arms to avoid lipohypertrophy. At 10 mg/mL every step in this protocol draws small volumes, from 5 units at 500 mcg to 20 units at 2.0 mg, so each dose fits comfortably in one U-100 insulin syringe and no dose needs to be split across two injections.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: 500 mcg daily, 5 units per injection, the entry step used to assess tolerance before any increase.
• Weeks 3 to 4: 1.0 mg daily, 10 units per injection, the first step up.
• Weeks 5 to 8: 1.5 mg daily, 15 units per injection. An 8 week course ends here.
• Weeks 9 to 12: 2.0 mg daily, 20 units per injection, for a course extended to 12 weeks.
• Across the course: many protocols hold at the 1 to 1.5 mg range instead of advancing to the top of the dose range.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 500 mcg = 5 units (0.05 mL) and 2.0 mg = 20 units (0.20 mL).

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at minus 20 °C (minus 4 °F) in dry, dark conditions; stable for 12 or more months.
• Reconstituted: refrigerate at 2 to 8 °C (35.6 to 46.4 °F) and avoid freeze-thaw cycles.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Keep the reconstituted vial protected from light and inspect it before each draw; a solution that is cloudy, discolored, or carrying visible particles is discarded.

Supplies Needed

The figures below are based on the daily course of 8 to 12 weeks with gradual titration, which works out to 3.5 mg per week at 500 mcg daily, 7 mg per week at 1.0 mg daily, 10.5 mg per week at 1.5 mg daily, and 14 mg per week at 2.0 mg daily.

Peptide Vials (Vesugen, 20 mg vial):

• Summed across the titration steps, an 8 week course uses about 63 mg, which is 4 vials of 20 mg, and a 12 week course uses about 119 mg, which is 6 vials.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes, one per day, since every dose in the range draws into a single syringe.
• Full course: 56 syringes over 8 weeks, or 84 syringes over 12 weeks.

Bacteriostatic Water (10 mL bottles):

• Each 20 mg vial takes 2.0 mL, so one 10 mL bottle covers 5 vials, which is 1 bottle for the 4 vial course of 8 weeks and 2 bottles for the 6 vial course of 12 weeks.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, which is 14 per week.
• Full course: 112 swabs over 8 weeks, or 168 over 12 weeks, so 2 boxes of 100 count cover either length.

Important Notes

Practical considerations for consistency and safety.

• Use a new sterile insulin syringe for every dose and dispose of it in a sharps container.
• Rotate injection sites to reduce local irritation, inject slowly, and wait a few seconds before withdrawing the needle.
• Gradual titration is the point of this schedule. Holding two weeks at each of the lower steps allows tolerance to be assessed before the dose rises, and many protocols stabilize at 1 to 1.5 mg rather than pushing to 2 mg.
• Document the daily dose, the injection site, and the reconstitution date on the vial label to keep the course consistent across 8 to 12 weeks.
• At 10 mg/mL a 20 mg vial holds 2.0 mL, which covers 40 days at 500 mcg, 20 days at 1.0 mg, about 13 days at 1.5 mg, and 10 days at 2.0 mg, so a fresh vial is reconstituted roughly every one to two weeks once the upper steps are reached.
• Regulatory Note: Vesugen is not an approved drug. It has no FDA approval and no approval from any other major regulatory agency for human use, and human clinical data remain limited, with most of the evidence coming from in vitro and rodent work. It is sold for research use only and is not for human consumption.

How This Works

Vesugen belongs to a class of ultrashort peptide bioregulators studied by Khavinson and colleagues. These tripeptides are proposed to enter cells and bind regulatory regions of DNA, modulating gene expression at nanomolar concentrations. Preclinical research suggests Vesugen upregulates Ki-67, a proliferation marker, in vascular endothelium, and supports the expression of genes involved in vascular homeostasis and angiogenesis. Human clinical data remain limited, and most of the available evidence comes from in vitro and rodent studies rather than controlled human trials.

Benefits & Side Effects

Observations from the published record.

• Preclinical models suggest support for vascular endothelial proliferation and function.
• Increased Ki-67 expression in vascular endothelium is the proliferation signal most often reported in the preclinical literature.
• May modulate aging-related gene expression markers in vascular tissue, including genes tied to vascular homeostasis and angiogenesis.
• Ultrashort peptides of this class generally exhibit favorable tolerability profiles in preclinical work.
• Human safety and efficacy data remain limited; mild injection-site reactions such as redness and itch may occur.

Lifestyle Factors

Complementary strategies for best outcomes.

• Support cardiovascular health with regular aerobic exercise.
• Maintain a nutrient-dense diet emphasizing omega-3 fatty acids and antioxidants.
• Prioritize quality sleep and stress management to support vascular function.
• Avoid smoking and excessive alcohol consumption.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Khavinson VK. Peptides and Ageing (review of bioregulatory peptide mechanisms).
2. Khavinson VK et al. Peptide regulation of gene expression: systematic review.